The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Immunotherapy followed by cetuximab in locally advanced/metastatic (LA/M) cutaneous squamous cell carcinomas (cSCC): The I-TACKLE trial.
 
Paolo Bossi
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Merck; MSD Oncology; Regeneron
Consulting or Advisory Role - Angelini Pharma; Bristol-Myers Squibb; GlaxoSmithKline; Merck Serono; MSD Oncology; Sanofi/Regeneron; Sun Pharma
Research Funding - Amgen (Inst); GlaxoSmithKline (Inst); Merck Serono (Inst); MSD Oncology (Inst); Regeneron (Inst); Roche (Inst)
 
Andrea Alberti
No Relationships to Disclose
 
Cristiana Bergamini
No Relationships to Disclose
 
Carlo Resteghini
Honoraria - Sun Pharma
 
Laura Deborah Locati
Honoraria - Biogen; McCann Health
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Eisai; IPSEN; Lilly; Merck Serono; MSD
Research Funding - Eisai (Inst)
Travel, Accommodations, Expenses - BMS; Eisai; Merck Serono; MSD
 
Salvatore Alfieri
No Relationships to Disclose
 
Stefano Cavalieri
No Relationships to Disclose
 
Elena Colombo
No Relationships to Disclose
 
Cristina Gurizzan
No Relationships to Disclose
 
Luigi Lorini
No Relationships to Disclose
 
Valeria Tovazzi
No Relationships to Disclose
 
Manuel Zamparini
No Relationships to Disclose
 
Marco Ravanelli
No Relationships to Disclose
 
Paolo Antonio Ascierto
Stock and Other Ownership Interests - PrimeVax
Consulting or Advisory Role - 4SC; Alkermes; Array BioPharma; AstraZeneca; Bio-AI Health; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Idera; Immunocore; Incyte; Italfarmaco; ITeos Therapeutics; Lunaphore Technologies; Medicenna; MedImmune; Merck Serono; Merck Sharp & Dohme; Nektar; Nouscom; Novartis; OncoSec; Pfizer; Pierre Fabre; Regeneron; Roche/Genentech; Sandoz; Sanofi; Seagen; Sun Pharma; Takis Biotech; Ultimovacs
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Vittorio Rampinelli
No Relationships to Disclose
 
Alberto Grammatica
No Relationships to Disclose
 
Roberto Patuzzo
No Relationships to Disclose
 
Andrea Maurichi
Speakers' Bureau - Novartis Italy
Travel, Accommodations, Expenses - Novartis Italy
 
Lisa F. Licitra
Consulting or Advisory Role - ACC Med+Logistics; Adlai Nortye; AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Debiopharm Group; Eisai; Exelixis; GlaxoSmithKline; IRX Therapeutics; Medpace; Merck Serono; MSD; Neutron Therapeutics; Novartis; Pfizer; Roche; Roche
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Debiopharm Group (Inst); Eisai (Inst); Exelixis (Inst); IRX Therapeutics (Inst); Medpace (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst)